Patents for software and diagnostic methods are now subject to increased scrutiny under § 101, § 112(a), and § 112(b), both in the courts and at the USPTO. Dave Easwaran was an invited speaker on a panel that summarized how the developments in each of these areas affect the use of functional claim language.
The panelists provided an overview of changes in the determinations of patent eligibility, written description, enablement, definiteness, and means-plus-function interpretation, and outlined a series of best practices for patent drafting, prosecution, and portfolio management that address the more thorough evaluation that functional claims are likely to face in the future.
For more information, please click here .
September 12, 2016
New York Hilton Hotel / New York, NY
The panelists provided an overview of changes in the determinations of patent eligibility, written description, enablement, definiteness, and means-plus-function interpretation, and outlined a series of best practices for patent drafting, prosecution, and portfolio management that address the more thorough evaluation that functional claims are likely to face in the future.
For more information, please click here .
September 12, 2016
New York Hilton Hotel / New York, NY